Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.

@article{1996ClinicalUI,
  title={Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.},
  author={},
  journal={MMWR. Morbidity and mortality weekly report},
  year={1996},
  volume={45 42},
  pages={
          921-5
        }
}
  • Published 1996
  • Medicine
  • MMWR. Morbidity and mortality weekly report
  • In 1995 and 1996, the Food and Drug Administration (FDA) approved three products in the new protease inhibitor class of drugs--saquinavir (Invirase), ritonavir (Norvir), and indinavir (Crixivan). Another drug in this class of agents, nelfinavir (Viracept) (Agouron Pharmaceuticals), is expected to be available soon from the manufacturer through an expanded-access program. All four drugs, which inhibit HIV protease and thus interfere with viral maturation and replication, are the most potent… CONTINUE READING
    26 Citations
    Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis.
    • 80
    • PDF
    Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India.
    • G. Ramachandran, P. K. Bhavani, +6 authors S. Swaminathan
    • Medicine
    • The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
    • 2013
    • 9
    Report of the NIH Panel to Define Principles of Therapy of HIV Infection.
    • S. Hewitt
    • Medicine
    • MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports
    • 1998
    • 80
    • PDF